免疫介导的炎症性疾病相关葡萄膜炎的培塞利珠单抗长期随访：80 例患者的多中心研究。
Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients.
机构信息
Rheumatology, Hospital Comarcal de Laredo, Laredo, Spain.
Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
出版信息
RMD Open. 2022 Dec;8(2). doi: 10.1136/rmdopen-2022-002693.
OBJECTIVES
To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).
METHODS
Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.
RESULTS
We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), CONCLUSIONS: CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.
目的
评估培塞利珠单抗（CZP）在免疫介导的炎症性疾病（IMID）相关葡萄膜炎中的疗效和安全性。
方法
对免疫介导的炎症性疾病相关葡萄膜炎患者进行 CZP 治疗的多中心研究，这些患者对常规免疫抑制剂治疗反应不佳。通过以下眼部参数评估疗效：最佳矫正视力、前房细胞、虹膜炎、黄斑厚度和视网膜血管炎。这些变量在基线、第 1 周、第 1、3、6 个月、第 1 年和第 2 年进行比较。
结果
我们研究了 80 名（33 名男性/47 名女性）患有 IMID 的患者（111 只受累眼），平均年龄为 41.6±11.7 岁。IMID 包括：脊柱关节炎（n=43）、贝赫切特病（n=10）、银屑病关节炎（n=8）、克罗恩病（n=4）、结节病（n=2）、幼年特发性关节炎（n=1）、反应性关节炎（n=1）、类风湿关节炎（n=1）、复发性多软骨炎（n=1）。
结论
CZP 似乎对不同的 IMID 相关葡萄膜炎有效且安全，即使在对先前的生物药物治疗反应不佳的患者中也是如此。
Zotero 插件